The Emerging Roles of Nanocarrier Drug Delivery System in Treatment of Intervertebral Disc Degeneration-Current Knowledge, Hot Spots, Challenges and Future Perspectives
DOI: https://doi.org/10.2147/dddt.s448807
IF: 4.3188
2024-03-30
Drug Design Development and Therapy
Abstract:Yunxiang Hu, 1, 2, &ast Rui Yang, 1, 2, &ast Sanmao Liu, 1, 2, &ast Zefeng Song, 3 Hong Wang 1, 2 1 Department of Orthopedics, Central Hospital of Dalian University of Technology, Dalian City, Liaoning Province, People's Republic of China; 2 School of Graduates, Dalian Medical University, Dalian City, Liaoning Province, People's Republic of China; 3 School of Graduates, Dalian University of Technology, Dalian City, Liaoning Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hong Wang Department of Orthopedics, Central Hospital of Dalian University of Technology, No. 826, Southwestern Road, Shahekou District, Dalian City, Liaoning Province, People's Republic of China , Email Low back pain (LBP) is a common condition that has substantial consequences on individuals and society, both socially and economically. The primary contributor to LBP is often identified as intervertebral disc degeneration (IVDD), which worsens and leads to significant spinal problems. The conventional treatment approach for IVDD involves physiotherapy, drug therapy for pain management, and, in severe cases, surgery. However, none of these treatments address the underlying cause of the condition, meaning that they cannot fundamentally reverse IVDD or restore the mechanical function of the spine. Nanotechnology and regenerative medicine have made significant advancements in the field of healthcare, particularly in the area of nanodrug delivery systems (NDDSs). These approaches have demonstrated significant potential in enhancing the efficacy of IVDD treatments by providing benefits such as high biocompatibility, biodegradability, precise drug delivery to targeted areas, prolonged drug release, and improved therapeutic results. The advancements in different NDDSs designed for delivering various genes, cells, proteins and therapeutic drugs have opened up new opportunities for effectively addressing IVDD. This comprehensive review provides a consolidated overview of the recent advancements in the use of NDDSs for the treatment of IVDD. It emphasizes the potential of these systems in overcoming the challenges associated with this condition. Meanwhile, the insights and ideas presented in this review aim to contribute to the advancement of precise IVDD treatment using NDDSs. Keywords: lumbar disc herniation, intervertebral disc degeneration, nanocarrier drug delivery system, targeted therapy, regenerative medicine Low back pain (LBP) is a widespread public health issue that results in profound and long-lasting disability, placing a substantial economic burden on both society and individuals affected by it. 1 Based on recent research, it is estimated that over 1/4 of adults will encounter LBP at some stage during their lifetime. Furthermore, approximately 10% of individuals with LBP will develop persistent disabilities. 2,3 The growing elderly population has led to a substantial rise in the economic impact of LBP. LBP has emerged as a prominent health issue exerting a substantial influence on public health and patients' quality of life. The origins of LBP are multifaceted and involve a wide range of factors, including genetic predisposition, lifestyle choices, and the natural process of aging. 4 While the origins of LBP are multifaceted, IVDD stands as the prevailing cause, characterized by evident structural alterations resulting from aging or mechanical strain. 5,6 The intervertebral disc (IVD) is a type of fibrocartilage that acts as a connective tissue between neighboring vertebrae, providing flexibility and helping to distribute pressure. Over time, the IVD undergoes wear and tear due to ongoing mechanical stress during development and the aging process, leading to dysfunction and degeneration of the disc. 7,8 Scientific research has provided evidence that the progressive degradation of the ECM, changes in the cellular properties of IVD cells, heightened cellular aging and mortality, and excessive inflammatory reactions are widely acknowledged as substantial factors in the initiation and advancement of IVDD. These factors exacerbate the disorder and disrupt the normal functioning of the IVD. 9–11 Presently, the majority of patients rely on rest or conservative therapies as the primary approach to alleviate pain associated with IVDD. Additionally, various medications including non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and other blockers are commonly used. In cases where these treatments prove ineffective, surgical interventions are typically employed to relieve symptoms and improve the quality of life for patients. 12,13 -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal